EGFR and glomerulosclerosis: The detrimental role of EGFR in GN is supported by a study in a type 2 diabetes mouse model where EGFR inhibition with Erlotinib (a selective, clinically used EGFR inhibitor) resulted in decreased albuminuria and glomerulosclerosis, attenuated podocyte loss, and reduced renal fibrosis (Li et al., 2018).